Inhibrx Biosciences, Inc. INBX

Rank #1056 · Nasdaq · $1.1B market cap

Audited by BDO USA, P.C., no going-concern flag in the latest filing.

Score

54.2

P/E

0.6

P/B

24.21

ROE

3879.2%

Op. Margin

-165724.0%

Debt Ratio

108%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆

Average

P/E 0.6x, P/B 24.21x. Ranks in the top 43% of the universe.

Profitability ★★☆☆☆

Average

ROE 3879.2%. Ranks in the top 50% of the universe.

Safety ★★★☆☆

Average

Debt ratio 108%. Ranks in the top 42% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 88.9% year over year. Ranks in the top 99% of the universe.

Valuation is the relative strength · Growth is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2024	$0.0B	$-0.2B	$-0.2B	$0.1B	-12178.9	455
2025	$0.0B	$-0.3B	$1.7B	$0.0B	-165724.0	108